Age-Related Macular Degeneration

Age-Related Macular Degeneration Recent News

Unity Biotechnology Stock Falls After Updated Data From Wet AMD Candidate
Graybug Vision Posts Six-Month Extension GB-102 Data Of Wet AMD Trial
Graybug Vision Inc (NASDAQ: GRAY) has provided a full-data analysis from the 18-month Phase 2b ALTISSIMO trial of GB-102 for wet age-related macular degeneration (wet AMD).
AbbVie, RegenXBio Ink $1.75B Retinal Gene Therapy Collaboration
Regeneron Touts Mid-Stage Win For Higher Dose Of Eylea In Age-related Macular Degeneration
Unity Biotech's UBX1325 Shows Initial Efficacy With Improved Vision, Structure In Vascular Eye Disease
Iveric Bio Reveals Positive Post-Hoc Analyses Of Zimura In Dry Age-Related Macular Degeneration
Stealth Bio Stock Almost Doubles After Positive Elamipretide Data In Eye Disease Study
Lineage Cell's Dry Age-Related Macular Degeneration Cell Therapy Associated With Stable Or Improved Vision
Lineage's Lead Candidate Used To Treat Patient With Retinal Disease Under Compassionate Use
Annexon Shares Gain After Patient Dosing Starts In Mid-Stage Study For Vision Loss Disorder Therapy
Annexon Inc (NASDAQ: ANNX) has 
Opthea Outlines OPT-302 Pivotal Study Designs In Chronic Eye Disorder
Ocular Therapeutix's Intravitreal Implant Shows Decrease In Retinal Fluid In Early-Stage Wet AMD Study
Gemini Therapeutics Completes 60 Patients Enrollment In Lead Candidate Mid-Stage Study In Dry AMD
EyePoint Pharma Prices $100M Equity Offering At $11 A Piece
Why Avalanche Biotechnologies Is Coming Off A Big Day

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved